MUNICH, Oct. 12, 2019 /PRNewswire/ -- Daiichi Sankyo Europe GmbH (hereafter, "Daiichi Sankyo") today announced one-year follow-up results from an analysis of 12,574 European non-valvular atrial fibrillation (NVAF) patients, mostly elderly, treated with edoxaban (known by the brand name...
For more information, please visit
https://prnmedia.prnewswire.com:443/news[...]ixiana-edoxaban-300937477.html